NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES
DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS
ANNOUNCEMENT.

Oslo, 19 September 2025: Reference is made to the stock exchange announcements
published by Navamedic ASA (the "Company") on 23 June 2025 and 14 July 2025,
regarding the contemplated partly underwritten rights issue to raise gross
proceeds of between NOK 110 million and NOK 130 million (the "Rights Issue") and
the approval of the Rights Issue by the extraordinary general meeting of the
Company.

The Financial Supervisory Authority of Norway (Nw. Finanstilsynet) has today, on
19 September 2025, approved a prospectus prepared by the Company in connection
with the Rights Issue and the listing on the Oslo Stock Exchange of up to
6,046,511 offer shares in the Rights Issue and up to 272,090 new shares to be
issued in connection with the settlement of the underwriting fee to the
underwriters in the Rights Issue (the "Prospectus"). The Prospectus is prepared
in accordance with the simplified disclosure regime for secondary issuances as
set out in the EU Prospectus Regulation (Regulation (EU) 2017/1129 of the
European Parliament and of the Council of 14 June 2017 and ancillary regulation,
as implemented under Norwegian law).

The subscription period for the Rights Issue will commence on 22 September 2025
at 09:00 hours (CEST) and expire on 6 October 2025 at 16:30 hours (CEST). The
subscription rights in the Rights Issue will be tradable on the Oslo Stock
Exchange under the ticker code "NAVAT" from 09:00 hours (CEST) on 22 September
2025 to 16:30 hours (CEST) on 30 September 2025.

Subject to applicable local securities laws, the Prospectus, including the
subscription form for the Rights Issue, will be made available at the Company's
website www.navamedic.com (http://www.navamedic.com), as well as
www.dnb.no/emisjoner (http://www.dnb.no/emisjoner) and
www.nordea.com/en/issuances (http://www.nordea.com/en/issuances). Printed copies
of the Prospectus may be obtained free of charge by contacting DNB Carnegie, a
part of DNB Bank ASA (Tel: +47 91 50 48 00) or Nordea Corporate Finance, a part
of Nordea Bank Abp, filial i Norge (Tel: +47 24 01 34 62).

The Company has retained DNB Carnegie, a part of DNB Bank ASA and Nordea
Corporate Finance, a part of Nordea Bank Abp, filial i Norge as managers for the
Rights Issue (the "Managers"). Advokatfirmaet Thommessen AS is engaged as
Norwegian legal counsel for the Company in connection with the Rights Issue.

For more information, please contact:

Kathrine Elisabeth Gamborg Andreassen, CEO, Navamedic ASA

Tel: +47 951 78 880

Email: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic ASA

Tel: +47 917 62 842

Email: lars.hjarrand@navamedic.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

About Navamedic ASA

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in Greece.
Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

- IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this document may not be sent to
jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The securities of the Company may not be offered or
sold in the United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act").
The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to "qualified institutional
buyers" as defined in Rule 144A under the U.S. Securities Act. No public
offering of the securities will be made in the United States.

Any offering and listing of the securities referred to in this announcement will
be made by means of the Prospectus. This announcement is an advertisement and is
not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European
Parliament and of the Council of 14 June 2017 on prospectuses to be published
when securities are offered to the public or admitted to trading on a regulated
market, and repealing Directive 2003/71/EC (as amended) as implemented in any
EEA Member State (the "Prospectus Regulation"). The approval of the Prospectus
by the Financial Supervisory Authority of Norway (Nw. Finanstilsynet) should not
be understood as an endorsement of the securities referred to in this
announcement. Investors should not subscribe for any securities referred to in
this announcement except on the basis of information contained in the
Prospectus, to fully understand the potential risks and rewards associated with
the decision to invest in the securities. Copies of the Prospectus will,
following publication, be available from the Company's registered office and,
subject to certain exceptions, on the website of the Managers.

In any EEA Member State other than Norway, this communication is only addressed
to and is only directed at qualified investors in that Member State within the
meaning of the Prospectus Regulation, i.e., only to investors who can receive
the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as "Relevant Persons"). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

This document is not for publication or distribution in, directly or indirectly,
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People's Republic of China or Japan or any other jurisdiction in
which such release, publication or distribution would be unlawful, and it does
not constitute an offer or invitation to subscribe for or purchase any
securities in such countries or in any other jurisdiction. In particular, the
document and the information contained herein should not be distributed or
otherwise transmitted into the United States or to publications with a general
circulation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their respective clients or for providing
advice in relation to the Rights Issue or any transaction or arrangement
referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date and are
subject to change without notice. This announcement is made by and is the
responsibility of, the Company. Neither the Managers nor any of their affiliates
makes any representation as to the accuracy or completeness of this announcement
and none of them accepts any responsibility for the contents of this
announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. No reliance may be
placed for any purpose on the information contained in this announcement or its
accuracy, fairness or completeness. Neither the Managers nor any of their
respective affiliates accepts any liability arising from the use of this
announcement.